MA49704A - Dérivés d'acide biliaire à marquage isotopique - Google Patents

Dérivés d'acide biliaire à marquage isotopique

Info

Publication number
MA49704A
MA49704A MA049704A MA49704A MA49704A MA 49704 A MA49704 A MA 49704A MA 049704 A MA049704 A MA 049704A MA 49704 A MA49704 A MA 49704A MA 49704 A MA49704 A MA 49704A
Authority
MA
Morocco
Prior art keywords
isotopic
labeled
acid derivatives
biliary acid
biliary
Prior art date
Application number
MA049704A
Other languages
English (en)
Inventor
Gabriel Galvin
Kevin Schaab
Matthew Yanik
Original Assignee
Intercept Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intercept Pharmaceuticals Inc filed Critical Intercept Pharmaceuticals Inc
Publication of MA49704A publication Critical patent/MA49704A/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J41/00Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0055Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives
    • C07J41/0061Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives one of the carbon atoms being part of an amide group
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J17/00Normal steroids containing carbon, hydrogen, halogen or oxygen, having an oxygen-containing hetero ring not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J17/005Glycosides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J9/00Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • C07J9/005Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05Isotopically modified compounds, e.g. labelled
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J41/00Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0094Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 containing nitrile radicals, including thiocyanide radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J51/00Normal steroids with unmodified cyclopenta(a)hydrophenanthrene skeleton not provided for in groups C07J1/00 - C07J43/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J9/00Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
MA049704A 2017-07-24 2018-07-23 Dérivés d'acide biliaire à marquage isotopique MA49704A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762536326P 2017-07-24 2017-07-24
US201762536609P 2017-07-25 2017-07-25

Publications (1)

Publication Number Publication Date
MA49704A true MA49704A (fr) 2021-03-31

Family

ID=65041285

Family Applications (1)

Application Number Title Priority Date Filing Date
MA049704A MA49704A (fr) 2017-07-24 2018-07-23 Dérivés d'acide biliaire à marquage isotopique

Country Status (12)

Country Link
US (2) US11472831B2 (fr)
EP (1) EP3658150A4 (fr)
JP (1) JP2020528892A (fr)
KR (1) KR20200031145A (fr)
CN (1) CN111050772A (fr)
AU (1) AU2018307611A1 (fr)
BR (1) BR112020001362A2 (fr)
CA (1) CA3070837A1 (fr)
IL (1) IL272119A (fr)
MA (1) MA49704A (fr)
MX (1) MX2020000873A (fr)
WO (1) WO2019023103A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202021595A (zh) 2018-08-10 2020-06-16 德商菲尼克斯製藥股份有限公司 用於預防及治療困難梭狀芽孢桿菌關聯疾病之異石膽酸或異別石膽酸及其氘化衍生物
WO2021023100A1 (fr) * 2019-08-06 2021-02-11 杜心赟 Composés d'acide désoxycholique, compositions pharmaceutiques et leurs utilisations
CN112898369B (zh) * 2019-12-04 2024-09-17 博瑞生物医药(苏州)股份有限公司 用于制备奥贝胆酸的方法
JP7755328B2 (ja) * 2021-09-09 2025-10-16 国立大学法人九州大学 重水素富化組成物、重水素置換されたカルボン酸の製造方法、反応促進剤及びカルボン酸を酸無水物に変換する化合物の使用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10113257C1 (de) 2001-03-19 2002-11-14 Inst Mikrotechnik Mainz Gmbh Elektrophoresevorrichtung und ihre Verwendung
PT2040713E (pt) 2006-06-27 2014-10-13 Intercept Pharmaceuticals Inc Para a prevenção ou o tratamento de doenças ou estados clínicos mediados por fxr
ES2663948T3 (es) 2008-11-19 2018-04-17 Intercept Pharmaceuticals, Inc. Moduladores de TGR5 y método de uso de los mismos
WO2013037482A1 (fr) * 2011-09-15 2013-03-21 Phenex Pharmaceuticals Ag Agonistes du récepteur du farnésoïde x pour le traitement et la prévention du cancer
NZ734451A (en) 2012-06-19 2018-12-21 Intercept Pharmaceuticals Inc Preparation, uses and solid forms of obeticholic acid
AU2013334122B2 (en) * 2012-10-26 2017-11-02 Intercept Pharmaceuticals, Inc. Process for preparing bile acid derivatives
CA2912139C (fr) 2013-05-14 2021-04-20 Roberto Pellicciari Derives 11-hydroxyle d'acides biliaires et leurs conjugues d'acides amines en tant que modulateurs du recepteur de farnesoide x
US20150112089A1 (en) 2013-10-22 2015-04-23 Metselex, Inc. Deuterated bile acids
CN105985396A (zh) * 2015-02-16 2016-10-05 苏州泽璟生物制药有限公司 氘代鹅去氧胆酸衍生物以及包含该化合物的药物组合物
WO2016168553A1 (fr) * 2015-04-17 2016-10-20 Concert Pharmaceuticals, Inc. Acide obéticholique deutéré
PE20180690A1 (es) 2015-04-27 2018-04-23 Intercept Pharmaceuticals Inc Composiciones de acido obeticolico y metodos de uso
EP3981779A1 (fr) 2015-10-07 2022-04-13 Intercept Pharmaceuticals, Inc. Modulateurs du récepteur farnésoïde x
WO2017147159A1 (fr) * 2016-02-23 2017-08-31 Enanta Pharmaceuticals, Inc. Dérivés d'acide biliaire utilisés deutérés utilisés comme agonistes de fxr/tgr5 et leurs méthodes d'utilisation
CN106008639B (zh) * 2016-03-11 2019-01-08 深圳市塔吉瑞生物医药有限公司 用于预防或治疗fxr-介导疾病的胆烷酸化合物

Also Published As

Publication number Publication date
KR20200031145A (ko) 2020-03-23
CA3070837A1 (fr) 2019-01-31
JP2020528892A (ja) 2020-10-01
AU2018307611A1 (en) 2020-02-06
US11472831B2 (en) 2022-10-18
WO2019023103A1 (fr) 2019-01-31
US20230057232A1 (en) 2023-02-23
US20200165290A1 (en) 2020-05-28
EP3658150A4 (fr) 2021-03-31
CN111050772A (zh) 2020-04-21
MX2020000873A (es) 2020-07-22
IL272119A (en) 2020-03-31
EP3658150A1 (fr) 2020-06-03
BR112020001362A2 (pt) 2020-08-11

Similar Documents

Publication Publication Date Title
MA49421A (fr) Formulations d'arn
EP3517528A4 (fr) Sel d'addition d'acide de dérivé de benzimidazole
EP3277381C0 (fr) Dérivés de nitrobenzyle d'agents anticancéreux
MA45478A (fr) Compositions de conjugués d'acides nucléiques ciblés
MA44725A (fr) Formulations d'un inhibiteur de lsd1
EP3426242A4 (fr) Icaritine et dérivés d'icaritine
MA54521A (fr) Dérivés d'oxopyridine substitués
EP3416647A4 (fr) Iminopyrimidinones substituées par n3 à titre d'agents antipaludéens
SI3927315T1 (sl) Okusne formulacije
EP3820980A4 (fr) Compositions d'esterquats
EP3408254A4 (fr) Sels de l'acide 5-aminolévulinique et dérivés
EP4043450A4 (fr) Dérivés 2h-benzopyrane utilisables en tant qu'inhibiteurs de crac
EP3600279A4 (fr) Formulations d'acide 1-amino-1-cyclopropanecaboxylique
EP3302061A4 (fr) Compositions d'urée à libération prolongée
MA49704A (fr) Dérivés d'acide biliaire à marquage isotopique
EP3600280A4 (fr) Formulations de chlorhydrate d'acide 1-amino-1-cyclopropanecarboxylique
EP3452441A4 (fr) Dérivés d'acide alpha-truxillique et compositions pharmaceutiques associées
EP3645548A4 (fr) Procédés de préparation d'acides biliaires
EP4013441A4 (fr) Formulations de larazotide
EP3316677A4 (fr) Activateur de passage d'acide jasmonique
EP3955910A4 (fr) Formulations à libération prolongée
EP3444345A4 (fr) Dérivé d'arnmicro-143
EP3377111A4 (fr) Promédicaments d'amine de composés pharmaceutiques
EP3681950A4 (fr) Pulvérisation d'acide tranexamique pour arthroplastie du genou
MA56504A (fr) Dérivés de pyridin-3-yle